BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 15008466)

  • 1. [Febrile neutropenia].
    Bally F; Marchetti O; Cometta A
    Rev Prat; 2003 Dec; 53(19):2101-7. PubMed ID: 15008466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antimicrobial therapy of febrile neutropenia--current developments].
    Karthaus M; Cornely OA; Südhoff T; Meran J
    Wien Med Wochenschr; 2001; 151(3-4):66-72. PubMed ID: 11789421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Possibilities and limits of ambulatory supportive measures in oncology exemplified by antibiotic therapy of febrile neutropenia].
    Karthaus M; Meran JG; Geissler RG; Böhme A; Jürgens H; Ganser A
    Wien Med Wochenschr; 1998; 148(18):427-32. PubMed ID: 9888179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives for the management of febrile neutropenic patients with cancer in the 21st century.
    Sipsas NV; Bodey GP; Kontoyiannis DP
    Cancer; 2005 Mar; 103(6):1103-13. PubMed ID: 15666328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early hospital discharge followed by outpatient management versus continued hospitalization of children with cancer, fever, and neutropenia at low risk for invasive bacterial infection.
    Santolaya ME; Alvarez AM; Avilés CL; Becker A; Cofré J; Cumsille MA; O'Ryan ML; Payá E; Salgado C; Silva P; Tordecilla J; Varas M; Villarroel M; Viviani T; Zubieta M
    J Clin Oncol; 2004 Sep; 22(18):3784-9. PubMed ID: 15365075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Infectious complications in pediatric cancer patients].
    Lehrnbecher T; Laws HJ
    Klin Padiatr; 2005 Nov; 217 Suppl 1():S3-8. PubMed ID: 16288349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Approach to treatment of the febrile cancer patient with low-risk neutropenia.
    Buchanan GR
    Hematol Oncol Clin North Am; 1993 Oct; 7(5):919-35. PubMed ID: 8226566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and implementation of a risk assessment tool for chemotherapy-induced neutropenia.
    Donohue R
    Oncol Nurs Forum; 2006 Nov; 33(2):347-52. PubMed ID: 16518450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
    Tamura K
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Diagnostic procedures and management of Fever in pediatric cancer patients].
    Laws HJ; Ammann RA; Lehrnbecher T
    Klin Padiatr; 2005 Nov; 217 Suppl 1():S9-16. PubMed ID: 16288350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic approach to a patient with febrile neutropenia].
    Duraković N; Nemet D
    Lijec Vjesn; 2007; 129(10-11):344-50. PubMed ID: 18257335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk assessment in fever and neutropenia in children with cancer: What did we learn?
    te Poele EM; Tissing WJ; Kamps WA; de Bont ES
    Crit Rev Oncol Hematol; 2009 Oct; 72(1):45-55. PubMed ID: 19195908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Empirical antibiotic therapy for febrile neutropenia].
    Kridel R; Van Delden C; Calandra T; Marchetti O
    Rev Med Suisse; 2008 Apr; 4(152):914, 916-9. PubMed ID: 18578432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outpatient management of febrile neutropenia: time to revise the present treatment strategy.
    Carstensen M; Sørensen JB
    J Support Oncol; 2008; 6(5):199-208. PubMed ID: 18551855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolving concepts of management of febrile neutropenia in children with cancer.
    Orudjev E; Lange BJ
    Med Pediatr Oncol; 2002 Aug; 39(2):77-85. PubMed ID: 12116054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applying the Multinational Association for Supportive Care in Cancer risk scoring in predicting outcome of febrile neutropenia patients in a cohort of patients.
    Baskaran ND; Gan GG; Adeeba K
    Ann Hematol; 2008 Jul; 87(7):563-9. PubMed ID: 18437382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bacterial infections in low-risk, febrile neutropenic patients.
    Kamana M; Escalante C; Mullen CA; Frisbee-Hume S; Rolston KV
    Cancer; 2005 Jul; 104(2):422-6. PubMed ID: 15937905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility of withholding antibiotics in selected febrile neutropenic cancer patients.
    Oude Nijhuis C; Kamps WA; Daenen SM; Gietema JA; van der Graaf WT; Groen HJ; Vellenga E; Ten Vergert EM; Vermeulen KM; de Vries-Hospers HG; de Bont ES
    J Clin Oncol; 2005 Oct; 23(30):7437-44. PubMed ID: 16234511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials.
    Sung L; Nathan PC; Lange B; Beyene J; Buchanan GR
    J Clin Oncol; 2004 Aug; 22(16):3350-6. PubMed ID: 15310780
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Febrile neutropenia in haematological malignancies.
    Sharma A; Lokeshwar N
    J Postgrad Med; 2005; 51 Suppl 1():S42-8. PubMed ID: 16519255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.